Microchip Biotech: Approval Notice for Clinical Trial of Sitagliptin and Metformin Extended-Release Tablets

MetaMuskRat · 2026-03-18T08:39:02+00:00

People Finance News March 16 - Microchip Biology (688321) announced on March 16 that the company and its wholly-owned subsidiary Chengdu Microchip Pharma Co., Ltd. recently received a "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company's product sitagliptin sodium metformin sustained-release tablets to proceed with clinical trials. Sitagliptin sodium metformin sustained-release tablets is a fixed-dose combination sustained-release formulation of sitagliptin sodium and metformin independently developed by the company. It treats type 2 diabetes through different mechanisms of action, enabling patients to achieve better blood glucose control.

MetaMuskRat

2026-03-18 08:39:02

People’s Financial News, March 16 — Microchip Biotech (688321) announced on March 16 that the company and its wholly owned subsidiary, Chengdu Microchip Pharmaceutical Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving the company’s product, Sitagliptin Sodium and Metformin Extended-Release Tablets, to conduct clinical trials. Sitagliptin Sodium and Metformin Extended-Release Tablets are a fixed-dose combination sustained-release formulation independently developed by the company, combining sitagliptin sodium and metformin to treat type 2 diabetes through different mechanisms, providing patients with better blood sugar control.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes